To determine the presentation, diagnosis, progression, and family risk of fibrotic myopathy, a disease with marked breed predisposition in the German Shepherd Dog (GSD).
41 dogs prospectively recruited to the University of Wisconsin-Madison Comparative Genetics and Orthopedic Laboratory between November 2019 to August 2022.
Medical records of dogs diagnosed with fibrotic myopathy were reviewed upon referral. The following data were recorded: sex, age, weight, regio interscapularis (withers) height, date of neutering, coat color and length, and age at fibrotic myopathy diagnosis. A pedigree was also obtained.
In the study population, breeds included 37 GSDs, a Belgian Malinois, a Belgian Malinois cross, and 2 dogs with a GSD phenotype and no pedigree. Mean age at fibrotic myopathy diagnosis was 5.9 ± 2.0 years, and duration of lameness before diagnosis was 5.6 months and ranged from 0.75 to 18 months. Males were overrepresented at 61% of the study population. Inherited familial risk for fibrotic myopathy in the GSD was supported by pedigree analysis.
This was the largest case series of fibrotic myopathy to date, providing a more comprehensive look at presentation and progression of the disease. The longer duration of lameness in bilaterally affected dogs likely represents disease progression rather than a more severe phenotype. Family history data support a genetic contribution to fibrotic myopathy, suggesting that further genetic investigation is warranted.
Objective—To evaluate concordance among veterinary
pathologists in the assessment of histologic findings
in the pars intermedia of pituitary gland sections
from aged horses with mild signs suggestive of pituitary
pars intermedia dysfunction (PPID).
Sample Population—10 pituitary glands from aged
Procedure—7 pathologists were provided with signalment,
clinical signs, and a single H&E-stained pituitary
gland section from 10 aged horses with mild
signs suggestive of PPID. Pathologists described histologic
findings for each section and stated whether
findings were consistent with PPID. Agreement
among pathologists and with antemortem diagnostic
test results was calculated.
Results—Overall, only fair agreement was found
among the pathologists as to which horses had histologic
findings consistent with disease (mean ± SE
kappa value, 0.34 ± 0.069). Interpretation of individual
sections varied, with minimal agreement (4 or 5/7
pathologists) for 5 of 10 sections evaluated.
Postmortem assessment was in agreement with an
antemortem endocrine diagnostic test result 79% of
Conclusions and Clinical Relevance—Validation of
antemortem diagnostic testing for PPID in horses
often relies on the results of postmortem histologic
evaluation. The lack of consensus in histologic interpretation
of pituitary glands from aged horses with
mild clinical signs in our study indicates that postmortem
histologic evaluation of pituitary glands is an
inappropriate standard in validation of antemortem
diagnostic tests for detection of early PPID. Caution
should be used when interpreting diagnostic test
results in horses in which early PPID is suspected.
(Am J Vet Res 2005;66:2055–2059)